Clinical Trials

Prostatic Neoplasms

NCT01314118 2026-02-24

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

131 enrolled 12 charts

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT02522715 2026-02-24

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

37 enrolled 10 charts

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT02257736 2026-02-13

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

982 enrolled 15 charts

Prostatic Neoplasms

NCT03338790 2026-01-27

CheckMate 9KD

292 enrolled 21 charts

Prostatic Neoplasms

NCT03565835 2026-01-26

Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer

31 enrolled 11 charts

Prostatic Neoplasms

NCT01995058 2026-01-08

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

54 enrolled 11 charts

Prostatic Neoplasms

NCT02985957 2025-12-22

CheckMate 650

351 enrolled 43 charts

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Prostatic Neoplasms

NCT03007732 2025-12-05

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

23 enrolled 14 charts

Prostatic Neoplasms

NCT03098836 2025-09-12

PANTHER

93 enrolled 17 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT03834506 2025-07-18

KEYNOTE-921

1,030 enrolled 24 charts

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT05288166 2025-06-27

CYCLONE 3

925 enrolled 12 charts

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT02903368 2025-06-13

Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

118 enrolled 23 charts

Prostatic Neoplasms

NCT04100018 2025-06-12

CheckMate 7DX

1,030 enrolled 25 charts

Prostatic Neoplasms

NCT03072238 2025-06-06

IPATential150

1,101 enrolled 35 charts

Prostatic Neoplasms

NCT03834519 2025-05-18

KEYLYNK-010

793 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT01848067 2025-05-04

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

9 enrolled 9 charts

Phase 2/3 Active not recruiting

Prostatic Neoplasms

NCT03706365 2025-04-20

CYCLONE 2

393 enrolled 23 charts

Prostatic Neoplasms

NCT04556617 2025-04-08

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 1/2 Terminated

19 enrolled 11 charts

Adenocarcinoma, Prostatic Neoplasms

NCT01309672 2025-02-26

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

41 enrolled 18 charts

Prostatic Neoplasms

NCT02043678 2025-02-19

ERA 223

806 enrolled 32 charts

Prostatic Neoplasms

NCT00887198 2025-02-04

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

1,088 enrolled 14 charts

Prostatic Neoplasms

NCT01715285 2025-02-04

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

1,209 enrolled 16 charts 1 FDA

Prostatic Neoplasms

NCT02218606 2024-12-10

Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer

81 enrolled 11 charts

Prostatic Neoplasms

NCT04907227 2024-07-12

KEYNOTE-921

Phase 3 Terminated

81 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT02903160 2024-02-07

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

40 enrolled 18 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT04887506 2024-01-16

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

107 enrolled 20 charts

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT01972217 2023-11-14

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

158 enrolled 32 charts

Prostatic Neoplasms

NCT03649841 2023-10-26

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

10 enrolled 7 charts

Prostatic Neoplasms

NCT01949337 2023-09-28

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Phase 3 Unknown

1,311 enrolled 12 charts

Prostatic Neoplasms

NCT01995513 2023-09-18

PLATO

Phase 4 Completed

509 enrolled 18 charts

Prostatic Neoplasms

NCT00004124 2022-12-30

S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer

983 enrolled 13 charts

Prostatic Neoplasms

NCT02494921 2022-08-31

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

43 enrolled 22 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT03279250 2022-08-10

Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer

86 enrolled 9 charts

Prostatic Neoplasms

NCT01681433 2022-07-11

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

72 enrolled 14 charts

Prostatic Neoplasms

NCT00288080 2022-06-21

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

612 enrolled 11 charts

Prostatic Neoplasms

NCT02268175 2022-04-19

Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate

75 enrolled 12 charts

Prostatic Neoplasms

NCT02849990 2022-01-13

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

22 enrolled 11 charts

Prostatic Neoplasms

NCT00134056 2021-10-27

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

1,038 enrolled 20 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT01503229 2021-05-14

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

32 enrolled 6 charts

Prostatic Neoplasms

NCT02685267 2021-04-09

Doce/Enza

9 enrolled 11 charts

Prostatic Neoplasms

NCT01468532 2021-03-25

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

18 enrolled 15 charts

Prostatic Neoplasms

NCT01940276 2020-12-09

Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer

100 enrolled 12 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT01051570 2020-12-01

Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

26 enrolled 9 charts

Prostatic Neoplasms

NCT01576172 2020-11-12

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

159 enrolled 12 charts

Prostatic Neoplasms

NCT00466440 2020-11-06

A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

108 enrolled 22 charts

Prostatic Neoplasms

NCT03093272 2020-04-09

A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer

9 enrolled 15 charts

Prostatic Neoplasms

NCT01946165 2019-12-06

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide

69 enrolled 9 charts

Prostatic Neoplasms

NCT01683994 2019-11-08

Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

49 enrolled 18 charts